Trial AMG 199 - 20180290

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

AMG 199 - 20180290

Full title

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 199 in Subjects with MUC17-Positive Gastric and Gastroesophageal Junction Cancer

Responsible organization

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

Indications

Classification	Code	Description
-		Stomach carcinoma

Trial design

Phase

Status

Recruitment active

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Sylvie	Lorenzen	3. Med 3. Med Ismaninger Str. 22 81675 München Germany